Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02508740 · ClinicalTrials.gov registry record · Phase 1
Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment
A Phase 1 study, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Terminated
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT02508740 is a Phase 1 study that was terminated before completion, run by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 31 participants.
The verdict
NCT02508740, a Phase 1 study, was terminated before completion, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the effect of renal function on the PK of a 0.25 mg single oral dose of bevenopran in humans and to assess the safety and tolerability of bevenopran in patients with varying degrees of renal impairment and in healthy subjects.
Interventions
- DRUG bevenopran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2013-09 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)42 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02508740
The ClinicalTrials.gov registry entry for NCT02508740 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bevenopran is the first listed.
NCT02508740 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02508740 about?
NCT02508740 is a clinical study titled "Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment". The purpose of this study is to characterize the effect of renal function on the PK of a 0.25 mg single oral dose of bevenopran in humans and to assess the safety and tolerability of bevenopran in patients with varying degrees of renal impairment and in healthy subjects.
What is the current status of trial NCT02508740?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2013-09. Estimated completion is 2013-12.
What interventions are being tested in trial NCT02508740?
The interventions under investigation include: bevenopran (DRUG).
Who is sponsoring clinical trial NCT02508740?
This trial is sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.